

Supplementary Figure Legends and Supplementary Figures

Figure S1. Protein sequence alignment of EXP2 from 12 Plasmodium species. The secondary structure elements and domain boundaries as observed in the reference structure of *Pf*-EXP2 [26] are indicated on top of the alignment. The pair of strictly conserved cysteines engaged in a disulfide bridges is highlighted in green. Other highly conserved cysteines are highlighted in grey. Alignment performed in *Clustal-Ω* [122] and displayed with *ESPRIP3.0* [123]. Although the predicted signal sequence cleavage site is between residues 20-22, the magenta arrow indicates the observed cleavage site after the first cysteine in *Pf*-EXP2. Sequences were retrieved from www.PlasmoDB.org. Human pathogens: *P.falciparum*, *P.vivax*, *P.malariae*, *P.ovale* – Monkey pathogens: *P.knowlesi*, *P.cynomolgi*, *P.reichenowi* – Rodent pathogens: *P.berghei*, *P.yoelii*, *P.chabaudi* – Bird pathogens: *P.relictum*, *P.gallinaceum*. The species infecting monkeys have also been found in humans.

Figure S2. Protein sequence alignment for the core segment of PTEX150 from 10 Plasmodium species. (A) The secondary structure elements and domain boundaries as observed in the reference structure of *Pf*-PTEX150 [26] are indicated on top of the alignment. Alignment performed in *Clustal-Ω* and displayed with *ESPRIP3.0*. Human pathogens: *P.falciparum*, *P.vivax*, *P.malariae*, *P.ovale* – Monkey pathogens: *P.knowlesi*, *P.cynomolgi*, *P.reichenowi* – Rodent pathogens: *P.berghei*, *P.yoelii*, *P.chabaudi*. The species infecting monkeys have also been found in humans. Sequences were retrieved from www.PlasmoDB.org. **(B)** Matrix displaying the percentage of sequence identity.

Figure S3. Splayed surface representation of the EXP2/PTEX150 tetradecameric pore assembly. The EXP2 heptamer and EXP2/PTEX150 tetradecamer are shown in surface representation where three EXP2 (1, 2 and 7) and three PTEX150 (1', 6' and 7') subunits have been rendered transparent to show the geometry of the protein conducting path and the intricacy of the association between the soluble adaptor protein PTEX150 and the membrane protein EXP2. Subunits are labeled and colored as in Figures 3 and 4. A model helix (P) indicates the axis of the central pore along the protein-conducting path.


Figure S4. Comparison of three protein-conducting pores. Side, top and bottom views of **(A)** the anthrax protective antigen (PDB 3J9C) [47], a C₇-symmetric β pore-forming translocon with a ring of residues (φ-clamp, magenta) functioning as an acidic pH-sensing gate, **(B)** the rigid EXP2/PTEX150 tetradecamer and **(C)** the Sec61/SecY universal translocon (PDB 3MP7) [50]. Transmembrane regions (β-strands or α-helices) are colored in green or cyan, soluble regions are colored in grey. **(A)** and **(B)** are on the same scale, **(C)** is 2.4X the scale of **(A)** and **(B)**. For Sec61/SecY, the hydrophobic plug (yellow) and ring (magenta) regions seal the pore and prevent leakage of water and ions in the resting state or during translocation. The lateral gate provides an exit portal (dark dots) to partition transmembrane helices from the pore into the lipid bilayer.

Figure S5. Protein sequence alignment of the catalytic domains of AAA+ protein unfoldase/disaggregases *Pf-HSP101*, *Ec-ClpB*, and *Sc-HSP104*. For the sake of clarity, the N-terminal domains have been omitted. The secondary structure elements and domain boundaries as observed in the reference structure of *Pf-HSP101* [26] are indicated on top of the alignment. Alignment performed in *Clustal-W* and displayed with *ESPRIT3.0*. Nucleotide-Binding Domains (NBD) I and II, C-Terminal Domains (CTD) and middle domain (MD) are indicated. Walker A (-GxxxxG**K**T/S- x being any residue) and Walker B (-hhhh**DE**- h being any hydrophobic residue) motifs bearing the catalytic residues are indicated together with the pore loop (PL) tyrosines (Y280 and Y686) interacting with the polypeptidic backbone of denatured substrates. The *trans*-acting Arginine fingers (R360/R361 and R800) and the *cis*-acting Arginine finger (R859) are involved in *inter* and *intra*- protomer transition state stabilization, respectively.

Figure S6. Protein sequence alignment of the catalytic domains from aspartic proteases *P. vivax* Plasmeprin V, *P. falciparum* Plasmeprin V and *T. gondii* Aspartic Protease 5 involved in the proteolytic licensing of PEXEL and TEXEL motifs, respectively. Sequence alignment of the conserved catalytic domains of *Pv*-PlmV, *Pf*-PlmV and *Tg*-Asp5. Alignment performed in *Clustal-W* and displayed with *ESPRIT3.0*. The secondary structure elements and domain boundaries as observed in the reference structure of *Pv*-PlmV are indicated on top of the alignment [95]. Catalytic aspartates in conserved motifs **D₈₀TGS** and **D₃₁₇SGS/T** are underlined in green. The 7 conserved disulfide bonds are numbered and colored accordingly; the only non-bridged cysteine (C*) is not conserved between *Toxoplasma* and *Plasmodium*. A helix-turn-helix insertion also characteristic of *Plasmodium* is colored in magenta. Predicted C-terminal trans-membrane helices (TMH) responsible for ER- (in PlmV) or Golgi- (in Asp5) anchoring are indicated. *Pv*-PlmV has 540 residues, *Pf*-PlmV has 590 residues and *Tg*-Asp5 has 1012 residues. Sequences were retrieved from www.PlasmoDB.org and www.ToxoDB.org.

Figure S7. Sequences and properties of *Toxoplasma gondii* MYR vacuolar membrane proteins. Predicted signal sequences and trans-membrane helices are boxed in grey and yellow, respectively. Cysteines are boxed in red. Serine-phosphorylation sites are boxed in cyan; MYR1: S175, S227, S246 and S787 – MYR2: S157 and S162 – MYR3: S41, S52 and S115 – MYR4: S724. TEXEL vacuolar trafficking signals (-**RRL**-) processed by aspartic protease *Tg*-Asp5 are present in MYR1 and MYR4. For the MYR4 sequence, numbering adheres to the results from Cygan *et al.* resulting in a discrepancy with the sequence curated in www.ToxoDB.org where the encoded protein has an additional 60 residues at its N-terminus [109]. For this shorter protein, this results in the high-probability prediction of a signal sequence.

Figure S1: *Plasmodium* spp. Exported Protein-2 (EXP2) sequence alignments








Figure S3. Splayed surface representation of the EXP2/PTEX150 tetradecameric pore assembly. The EXP2 heptamer and EXP2/PTEX150 tetradecamer are shown in surface representation where three EXP2 (1, 2 and 7) and three PTEX150 (1', 6' and 7') subunits have been rendered transparent to show the geometry of the protein conducting path and the intricacy of the association between the soluble adaptor protein PTEX150 and the membrane protein EXP2. Subunits are labeled and colored as in Figures 3 and 4. A model helix (P) indicates the axis of the central pore along the protein-conducting path.

A Anthrax protective antigen pore (C7)



B EXP2/PTEX150 tetradecamer (C7)



C Sec61 $\alpha\beta\gamma$ /SecYEG (asymmetric)




Figure S4. Comparison of three protein-conducting pores. Side, top and bottom views of (A) the anthrax protective antigen (PDB 3J9C) [44], a C7-symmetric β pore-forming translocon with a ring of residues (ϕ -clamp, magenta) functioning as an acidic pH-sensing gate, (B) the rigid EXP2/PTEX150 tetradecamer and (C) the Sec61/SecY universal translocon (PDB 3MP7) [47]. Transmembrane regions (β -strands or α -helices) are colored in green or cyan, soluble regions are colored in grey. (A) and (B) are on the same scale, (C) is 2.4X the scale of (A) and (B). For Sec61/SecY, the hydrophobic plug (yellow) and ring (magenta) regions seal the pore and prevent leakage of water and ions in the resting state or during translocation. The lateral gate provides an exit portal (dark dots) to partition transmembrane helices from the pore into the lipid bilayer.

Figure S5: Sequence alignments of *Pf*-HSP101, *Ec*-ClpB and *Sc*-HSP104 Proteins





Figure S6: Aspartic Proteases Processing Vacuolar Trafficking Signals



MYR1 (gene TGGT1_254470)

MRCLVALLCL VSSTALEGAE **A**TRAELLSVC LISLSLTGCF CCQPVAATDE SDLGNAFEQQ **60**
 RKDSESESL NPEQEISGMP PONRNEGKNS SPMTSDTSTF QGERGTDSPK GGENAEAGFL **120**
 GSLGVDVAVLG ADGDDGYSDE DKAERGDPEF DMNSLDRQDQ ANPSEPRPSL PDEGSQQGHA **180**
 STGEPEVKSD NVKFISYAQK AEKNQPDGDF KGSESFSPSG FDYREGSPGV GDYRILNEGA **240**
 DSPTFSDHDY DDYDETSNGE LPLGRLRNKV QLTAAERY**CG** LKPKGPTVLY TPPGVRPDEL **300**
 EALDLFAVTD AGFFELLRDS HGDLV**CP**ERR RGERVLFNRL RLKNSELVGD MVYSDPRSYP **360**
 HMTQVHPDGK ATKTPRAPTE QKTPPRREDR GSKERSKSVE NSGKLSMWS RLL**CK**VSKRY **420**
CNTKVTGEKG QDEDSGDPTT HKRQPRQIVA AEVPLREVFG VKPLEIFDWK VKELLYRLDR **480**
 EMGQEGNLDE RMPYFAVPT EAAGRAPGVA QVPGSGSEGE TISHAGALQG DFQREPKGGD **540**
 AERRRESHET QNSAGAGRQA PASRTDAPVE AGQGDV**RRLS** EQAYNDNPEK APEQSGGALD **600**
 GGVDYPANDW LEAEYEDAPN ISIPDFLFSV PADRTHDDDE PNTMQEATS VDLKVTVLC **660**
 ENGAPPILIK EWPAFTNVVK PRKVLPOKPA VPRKS**VAVWG SSFLAAVAAG MYAI**KRLVNP **720**
 AALQYGSRYQ RLES**FSLLGW LAVFVLGSAQ LAGLLTW**NVR TAIHSSHLRH NLREELFADE **780**
 KAGTDG**S**AGS VYPTGFIFY DRHFRQSHNS **810**

MYR2 (gene TGGT1_270700)

MOSVADSAFV LIQFIAISEP PATVARTPOT RRRRGGRARL VR**ACWNASVF FLFWCLATWA** **60**
 QDRWTADLFI VEGEADTNFP MVDQPGGPAD RDGVAFERQD SGVDSGSQEV GDFDFENQFG **120**
 ADLGGQDGGT SMRDGDQRTT HNGALSLKSP TGGDTQ**SEAD** L**SG**ESSSGHE APKQGEPEEQ **180**
 GDPPGQAVIP QAPVANSDFG YRGHSQVQAA **PCVTRRC**PYY KQPTVEIEEE NVMRKKPAVV **240**
 SRKRQASEWY YGDEETTSK **VLRGVGYGWM AFMVYAI**IRH GMSNERTEPY YEEEQ **295**

MYR3 (gene TGGT1_237230)

MGRRESLVGF ETGKLDGSKV HSQEDKASDD TAADALETND **SSDNYGPRPP** **K**SEDAARLRK **60**
 IYEQAEHEGRK RQRKANFQ**AL** **LTSFGLVAVY AVSGFLFLRY** **A**TPRSKRPOQ VGGGS**DY**GLH **120**
 DGYPVRHDNW YIRDNPNPV LTMDQLF**ACE** SERREGDRVG IESFTD**CDGE** AIG**C**FFAIRT **180**
 SE**C**LERNQRD GRVYFEKKEL LDVDSSQAPP **LCS** **223**

MYR4 (gene TGGT1_211460)

MTTNRKGDVT VFRKERNQPS CTADVTMEGS **SACGIPVAGO** **NORMAPLRND** **VRYRRCPRVA** **-60**
MTPRGGFERR ASALVPLSLL VITLLTKAEG KSSSNTAKF ESHGAAQFSP LTVVNQPPAE **60**
 PLSAAVEHAV NNSNDPSGSH DPLLLNDGVD SDEGSRPSRQ EHEEADGWGQ FGSRHLADVT **120**
 QSGKQPQSED IQSGSQAGVA NHLSLAVGNS SSVKKEDEVO GMSDETEFEP SHSDPVGKRH **180**
RRLRGEGAA AEAADAVRQL SVEPSSVSDP PSHPOFGVEQ ESEFVTGAEK RPPPTAVPVA **240**
 TTRAVQPVGI GVLSTTTLLA KRALEEVGSL GRGIGLYLYG VVFRGNLLLO ANVLGKIKEN **300**
 IGVLEFVEEF QPQFAPSRA IVDELTVWQD TLQRVVQEQ AFVLQYQAYV SALREWSNRK **360**
 FHNDSGVHPT VSPVVDQAS QAPPDSAPAT EQFSSETARD VDEQEVLEPS RNADITESRG **420**
 PGDLGLMAPG GDMAPSSVPS NAEQVNAYEF QSKPASSLVQ VNDTGDYSAT RFARQVVNEK **480**
 PPYTPHLRES SLPSAQVAVT GQPGDDEFVA HEGPETSEVL RASHSTDAGP DLVENPPEID **540**
 RTSSAIDTEM TDVDSVVVAS QGSEAVHNNS NADATQGPFF VVPRGVRGPL TTPPSMHASA **600**
 GIPPFARKE DNDSADSPAK EVLPVSVAVD QHDEAIRESN GTKAPKEAGS SVLSTSHQNE **660**
 SSKGVALEDN SPGKSPSLPA VPVEGLPGTK AVGERIAAET EEAFSGSKGE TVHGLSTPE **720**
 WVD**SE**SDTER GLYGRQDSML LPPPDDVETL DLYLSLLQST FFK**C**GALLSR ALLADDSKEL **780**
 TWFYQEVLP S MSHLGRVIA VVASQHRRGV RSAASAERHL QKIRSMLFHV TVVDDAFLHA **840**
 IYARDEPPTS ERLEASDSDE YRKPANARARS QKTKKDKVKV EGTRVGAAIE FAKAHLVKP**W** **900**
VIGLLTFASL VGIDHYGNR YY **922**

Figure S7. Sequences and properties of *Toxoplasma gondii* MYR vacuolar membrane proteins. Predicted signal sequences and trans-membrane helices are boxed in grey and yellow, respectively. Cysteines are boxed in red. Serine-phosphorylation sites are boxed in cyan; MYR1: S175, S227, S246 and S787 – MYR2: S157 and S162 – MYR3: S41, S52 and S115 – MYR4: S724. TEXEL vacuolar trafficking signals (-**RRL**) processed by aspartic protease *Tg*-Asp5 are present in MYR1 and MYR4. For the MYR4 sequence, numbering adheres to the results from Cygan *et al.* resulting in a discrepancy with the sequence curated in www.ToxoDB.org where the encoded protein has an additional 60 residues at its N-terminus [109]. For this shorter protein, this results in the high-probability prediction of a signal sequence.